eCura system

The eCura system is a specialized medical tool designed to help clinicians assess the risk of lymph node metastasis (LNM) in early gastric cancer patients after endoscopic submucosal dissection (ESD). This evidence-based app simplifies risk stratification to guide post-treatment decisions, making it invaluable for gastroenterologists and surgeons.

Features of the eCura system:

- Risk Scoring System: Calculates LNM risk using weighted factors like lymphatic invasion, tumor size, and submucosal invasion depth.

- Three-Tier Risk Classification: Categorizes patients into low (0-1 points), intermediate (2-4 points), or high-risk (5-7 points) groups based on 2017 clinical study data.

- Educational Interface: Provides clear explanations of medical terminology and research findings.

- Multilingual Support: Includes translations for global accessibility.

- Disclaimer Integration: Clearly states its role as an educational tool, not a diagnostic replacement.

Tips for using the eCura system:

- Input accurate patient data (e.g., tumor measurements, histopathology results) for reliable scoring.

- Use the app to complement clinical judgment, not replace further diagnostic tests.

- Review the embedded study references (*Am J Gastroenterol. 2017*) to deepen understanding of the scoring methodology.

- Share results with multidisciplinary teams to streamline patient management plans.

Why use this app:

The eCura system transforms complex research into actionable insights, helping clinicians make data-driven decisions about additional surgeries or surveillance post-ESD. Backed by peer-reviewed validation, it reduces guesswork in managing early gastric cancer while improving patient counseling through visual risk categorization.

Conclusion:

For healthcare professionals treating early gastric cancer, the eCura system bridges cutting-edge research and clinical practice. Its intuitive design and evidence-based framework enhance precision in post-ESD care planning. However, users must remember it’s an educational aid—always prioritize comprehensive patient evaluation and institutional guidelines.